Australian biotech firm Terragen (ASX:TGH) announced binding commitments for a $7 million equity raising.
The capital injection, achieved through the issuance of new fully paid ordinary shares at $0.022 each, marks a pivotal moment for the company as it seeks to validate its product range.
The funding structure is bifurcated into two distinct tranches. The first involves an institutional placement of approximately $2.8 million utilising the company’s existing placement capacity.
The second, a conditional placement of $4.2 million, is subject to shareholder approval.
Non-executive Director Scobie Ward has demonstrated strong internal confidence by committing $2.3 million to the raising.
The capital boost significantly enhances Terragen's financial standing, bringing its pro forma cash position to approximately $9.8 million as of late 2025.
The proceeds are earmarked for high-impact initiatives: advancing research and development to diversify their biological product offerings and scaling their commercial footprint internationally.